Literature DB >> 35821454

The P2X1 receptor as a therapeutic target.

Felix M Bennetts1, Jesse I Mobbs1, Sabatino Ventura1, David M Thal2.   

Abstract

Within the family of purinergic receptors, the P2X1 receptor is a ligand-gated ion channel that plays a role in urogenital, immune and cardiovascular function. Specifically, the P2X1 receptor has been implicated in controlling smooth muscle contractions of the vas deferens and therefore has emerged as an exciting drug target for male contraception. In addition, the P2X1 receptor contributes to smooth muscle contractions of the bladder and is a target to treat bladder dysfunction. Finally, platelets and neutrophils have populations of P2X1 receptors that could be targeted for thrombosis and inflammatory conditions. Drugs that specifically target the P2X1 receptor have been challenging to develop, and only recently have small molecule antagonists of the P2X1 receptor been available. However, these ligands need further biological validation for appropriate selectivity and drug-like properties before they will be suitable for use in preclinical models of disease. Although the atomic structure of the P2X1 receptor has yet to be determined, the recent discovery of several other P2X receptor structures and improvements in the field of structural biology suggests that this is now a distinct possibility. Such efforts may significantly improve drug discovery efforts at the P2X1 receptor.
© 2022. The Author(s).

Entities:  

Keywords:  ATP; Bladder dysfunction; Drug discovery; Male contraception; Structural biology; Thrombosis and inflammation

Year:  2022        PMID: 35821454     DOI: 10.1007/s11302-022-09880-4

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.950


  110 in total

Review 1.  The therapeutic potential of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Biochem Pharmacol       Date:  2017-07-21       Impact factor: 5.858

Review 2.  ATP-Gated P2X Receptor Channels: Molecular Insights into Functional Roles.

Authors:  Ralf Schmid; Richard J Evans
Journal:  Annu Rev Physiol       Date:  2018-10-24       Impact factor: 19.318

Review 3.  P2X1: a unique platelet receptor with a key role in thromboinflammation.

Authors:  Cécile Oury; Odile Wéra
Journal:  Platelets       Date:  2021-03-24       Impact factor: 3.862

Review 4.  Heteromeric assembly of P2X subunits.

Authors:  Anika Saul; Ralf Hausmann; Achim Kless; Annette Nicke
Journal:  Front Cell Neurosci       Date:  2013-12-18       Impact factor: 5.505

Review 5.  To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?

Authors:  Leanne Stokes; Stefan Bidula; Lučka Bibič; Elizabeth Allum
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 6.  Purine and purinergic receptors.

Authors:  Geoffrey Burnstock
Journal:  Brain Neurosci Adv       Date:  2018-12-06

7.  Crystal structure of the ATP-gated P2X(4) ion channel in the closed state.

Authors:  Toshimitsu Kawate; Jennifer Carlisle Michel; William T Birdsong; Eric Gouaux
Journal:  Nature       Date:  2009-07-30       Impact factor: 49.962

Review 8.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

9.  New Insights Into Permeation of Large Cations Through ATP-Gated P2X Receptors.

Authors:  Laurie Peverini; Juline Beudez; Kate Dunning; Thierry Chataigneau; Thomas Grutter
Journal:  Front Mol Neurosci       Date:  2018-07-31       Impact factor: 5.639

Review 10.  Recommended tool compounds and drugs for blocking P2X and P2Y receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Purinergic Signal       Date:  2021-09-02       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.